Galectin Therapeutics Q2 EPS $(0.15) Beats $(0.21) Estimate
Portfolio Pulse from Happy Mohamed
Galectin Therapeutics reported Q2 losses of $(0.15) per share, beating the analyst consensus estimate of $(0.21) by 28.57 percent. This is a 6.25 percent increase over losses from the same period last year.
August 14, 2023 | 12:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Galectin Therapeutics reported better than expected Q2 losses, which could positively impact the stock in the short term.
Galectin Therapeutics reported a smaller loss than expected for Q2, which is generally seen as positive news by investors. This could lead to increased investor confidence and a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100